Publications by authors named "Bob Lowenberg"

Claim this Profile
D
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.
Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, Fleur Janssen, Laura Oudshoorn-van Marsbergen

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.
Lukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp, Jesse M Tettero, Lok Lam Ngai

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia.
Emma L Boertjes, Christian M Vonk, François G Kavelaars, Marie Engvall, Sofia Nordin

Blood Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
Tim R Mocking, Lukas H Haaksma, Tom Reuvekamp, Angèle Kelder, Willemijn J Scholten

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Anna J T Smit, Niek G Van der Maas, Bronno Van der Holt, Yvette Van Norden, Erik Van Werkhoven

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
Niek G van der Maas, Dimitri Breems, Clara P W Klerk, Thomas Pabst, Patrycja Gradowska

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, Yvette van Norden, Jeroen J W M Janssen

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early death and intracranial hemorrhage prediction in acute promyelocytic leukemia: validation of a risk score in a cohort from an international consortium treated with chemotherapy plus all- retinoic acid.
Wellington F Silva, Haesook T Kim, Maria S Undurraga, Juan R Navarro-Cabrera, Victor Salinas

Haematologica· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.
Christian M Vonk, Tim Grob, Melissa Rijken, François G Kavelaars, Jolinda M L Konijnenburg

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis.
Emma L Boertjes, Sanne Massaar, Annelieke Zeilemaker, Jolinda Konijnenburg, Melissa Rijken

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.
Dietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, Bart J Biemond, Haifa Al-Ali

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.
Tom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, Jannemieke Carbaat-Ham, Daphne den Hartog

Cytometry B Clin Cytom· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Gerwin Huls, Dana A Chitu, Lidwine Tick, Rinske Boersma, Dimitri Breems

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease characteristics and outcomes of acute myeloid leukemia in germline deficiency (Familial Platelet Disorder with associated Myeloid Malignancy).
Martijn P T Ernst, Jurjen Versluis, Peter J M Valk, Marc Bierings, Rienk Y J Tamminga

Hemasphere· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Stratification in Older Intensively Treated Patients With AML.
Jurjen Versluis, Marlen Metzner, Ariel Wang, Patrycja Gradowska, Abin Thomas

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Hartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, Charles Craddock, Hervé Dombret

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, Francesco Buccisano, Lok Lam Ngai

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luísa Corrêa de Araújo Koury, Haesook T Kim, Maria Soledad Undurraga, Juan Ramon Navarro-Cabrera, Victor Salinas

Blood· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of molecular measurable residual disease detection in AML with mutated .
Christian M Vonk, Emma L Boertjes, Francois G Kavelaars, Melissa Rijken, Jolinda M L Konijnenburg

Hemasphere· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients.
Adriane Halik, Marlon Tilgner, Patricia Silva, Natalia Estrada, Robert Altwasser

J Hematol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.
Michael V Martin, Salvador Aguilar-Rosas, Katka Franke, Mark Pieterse, Jamie van Langelaar

Cancer Immunol Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
Niek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, Joost van Rosmalen, Thomas Pabst

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.
Jesse M Tettero, Lok Lam Ngai, Costa Bachas, Dimitri A Breems, Thomas Fischer

Haematologica· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Single-Cell Taxonomy Predicts Inflammatory Niche Remodeling to Drive Tissue Failure and Outcome in Human AML.
Lanpeng Chen, Eline Pronk, Claire van Dijk, Yujie Bian, Jacqueline Feyen

Blood Cancer Discov· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.
Jacobien R Hilberink, Isabelle A van Zeventer, Dana A Chitu, Thomas Pabst, Saskia K Klein

Blood Cancer J· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis